由于在竞争中SubLOCADE的销售量减少,Indivior降低了2024年的收入预测。 Indivior lowers 2024 revenue forecast due to decreased SUBLOCADE sales amid competition.

Indivior PLC减少了其2024年的收入预测,原因是其类阿片成瘾治疗(SubLOCADE)销售令人失望,该类阿片成瘾治疗面临竞争产品的竞争。 Indivior PLC has reduced its 2024 revenue forecast due to disappointing sales of its opioid addiction treatment, SUBLOCADE, which faced competition from a rival product. 结果,伦敦的股票下降约15%,纳斯达克的市场前贸易下降17%。 As a result, shares fell by about 15% in London and 17% in pre-market trading on Nasdaq. 该公司现在预计调整后的业务利润在2.6亿至2.8亿美元之间,年度净收入为11.25亿美元至11.65亿美元,低于先前的估计。 The company now expects adjusted operating profit between $260 million and $280 million and annual net revenues of $1.125 billion to $1.165 billion, down from prior estimates.